BACKGROUND: Among @entity1 awaiting cadaveric lung transplantation, @entity1 with @entity16058 ( @entity16058 ) have been demonstrated to have the highest mortality rate. Contraindications to cadaveric lung transplantation include current high-dose systemic @entity228 therapy because it may increase airway complications and various types of @entity281 . STUDY OBJECTIVES: To analyze the effect of living-donor lobar lung transplantation (LDLLT) for @entity1 with advanced @entity16058 including those receiving high-dose systemic @entity288 . DESIGN: Retrospective analysis. SETTING: Okayama University Hospital and Okayama Medical Center. @entity1 : We report on the first nine @entity1 (seven female and two male; age range, 13 to 55 years) with advanced @entity16058 receiving LDLLT. All nine @entity1 had a very limited life expectancy, and eight @entity1 were dependent on systemic corticosteroid therapy as high as 50 mg/d of @entity229 . LDLLT was performed under cardiopulmonary bypass using two lower lobes donated by two healthy relatives. RESULTS: There were no airway complications in the 18 bronchial anastomoses. There was one early @entity204 (11%) due to severe acute rejection. Eight @entity1 (89%) are currently alive with a follow-up period of 10 to 48 months. Their vital capacity reached 2.03 +/- 0.20 L (mean +/- SEM), 71.4% of predicted at 1 year. All 18 donors have returned to their previous lifestyles. Excised lungs were pathologically diagnosed as @entity2416 ( @entity2416 ) in six cases and fibrotic @entity401 ( @entity401 ) in three cases. CONCLUSIONS: These early follow-up data support the option of LDLLT in @entity1 with advanced @entity16058 , including @entity2416 and @entity401 , who would die soon otherwise. Current high-dose systemic corticosteroid therapy is not a contraindication in LDLLT.

A new treatment strategy for advanced XXXX : living-donor lobar lung transplantation.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity16058 :: ('MESH:D054988', 'Disease') :: ['idiopathic interstitial pneumonia', 'IIP'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity2416 :: ('MESH:D054990', 'Disease') :: ['UIP', 'usual interstitial pneumonia'] @entity401 :: ('MESH:D017563', 'Disease') :: ['nonspecific interstitial pneumonia', 'NSIP', 'fibrotic NSIP'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity16058 :: (MESH:D054988,Disease) :: ['idiopathic interstitial pneumonia']
